Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMY Bristol Myers Squibb	$56.76 +0.7%	$58.74	$42.52 ▼ $62.89	$115.15B	0.26	10.21 million shs	7.69 million shs
CSLLY CSL	$17.55 -1.3%	$23.71	$17.53 ▼ $44.86	$34.54B	0.69	423,399 shs	704,963 shs
GSK GSK	$50.91 -0.2%	$54.47	$35.45 ▼ $61.69	$103.47B	0.38	4.24 million shs	3.53 million shs
VRTX Vertex Pharmaceuticals	$450.41 -0.6%	$446.38	$362.50 ▼ $507.92	$114.99B	0.3	1.10 million shs	1.09 million shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMY Bristol Myers Squibb	+0.64%	+1.03%	-2.28%	-6.39%	+28.83%
CSLLY CSL	-1.35%	-19.53%	-29.11%	-66.89%	-77.10%
GSK GSK	-0.07%	+0.84%	-13.99%	-13.62%	+40.43%
VRTX Vertex Pharmaceuticals	-0.58%	+5.98%	+1.38%	-8.35%	+6.95%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMY Bristol Myers Squibb	$56.76 +0.7%	$58.74	$42.52 ▼ $62.89	$115.15B	0.26	10.21 million shs	7.69 million shs
CSLLY CSL	$17.55 -1.3%	$23.71	$17.53 ▼ $44.86	$34.54B	0.69	423,399 shs	704,963 shs
GSK GSK	$50.91 -0.2%	$54.47	$35.45 ▼ $61.69	$103.47B	0.38	4.24 million shs	3.53 million shs
VRTX Vertex Pharmaceuticals	$450.41 -0.6%	$446.38	$362.50 ▼ $507.92	$114.99B	0.3	1.10 million shs	1.09 million shs

Analysts Agree—These Gold Picks Outshine the Rest

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMY Bristol Myers Squibb	+0.64%	+1.03%	-2.28%	-6.39%	+28.83%
CSLLY CSL	-1.35%	-19.53%	-29.11%	-66.89%	-77.10%
GSK GSK	-0.07%	+0.84%	-13.99%	-13.62%	+40.43%
VRTX Vertex Pharmaceuticals	-0.58%	+5.98%	+1.38%	-8.35%	+6.95%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMY Bristol Myers Squibb	2.37	Hold	$61.31	8.01% Upside
CSLLY CSL	2.25	Hold	N/A	N/A
GSK GSK	1.90	Reduce	$53.00	4.11% Upside
VRTX Vertex Pharmaceuticals	2.85	Moderate Buy	$555.17	23.26% Upside

Current Analyst Ratings Breakdown

Latest CSLLY, BMY, VRTX, and GSK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/11/2026	CSLLY CSL	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
5/11/2026	CSLLY CSL	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/6/2026	VRTX Vertex Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$607.00 ➝ $615.00
5/5/2026	VRTX Vertex Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$612.00 ➝ $616.00
5/5/2026	VRTX Vertex Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$541.00 ➝ $543.00
5/5/2026	VRTX Vertex Pharmaceuticals	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$577.00 ➝ $572.00
5/5/2026	VRTX Vertex Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$437.00 ➝ $436.00
5/1/2026	GSK GSK	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B)
5/1/2026	BMY Bristol Myers Squibb	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
4/30/2026	VRTX Vertex Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$441.00 ➝ $437.00
4/27/2026	VRTX Vertex Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMY Bristol Myers Squibb	$48.19B	2.41	$8.19 per share	6.93	$9.84 per share	5.77
CSLLY CSL	$15.56B	2.19	$2.16 per share	8.13	$11.05 per share	1.59
GSK GSK	$43.07B	2.40	$6.00 per share	8.49	$11.57 per share	4.40
VRTX Vertex Pharmaceuticals	$12.00B	9.53	$17.47 per share	25.78	$76.29 per share	5.90

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMY Bristol Myers Squibb	$7.05B	$3.56	15.94	9.38	0.16	15.01%	64.87%	13.16%	7/30/2026 (Estimated)
CSLLY CSL	$3.00B	N/A	N/A	10.32	3.17	N/A	N/A	N/A	N/A
GSK GSK	$7.54B	$3.85	13.23	9.90	2.60	17.82%	44.28%	11.49%	7/29/2026 (Estimated)
VRTX Vertex Pharmaceuticals	$3.95B	$16.86	26.71	23.67	1.94	35.51%	23.86%	17.13%	8/3/2026 (Estimated)

Latest CSLLY, BMY, VRTX, and GSK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/4/2026	Q1 2026	VRTX Vertex Pharmaceuticals	$4.24	$4.47	+$0.23	$4.02	$2.99 billion	$2.99 billion
4/30/2026	Q1 2026	BMY Bristol Myers Squibb	$1.42	$1.58	+$0.16	$1.31	$10.93 billion	$11.49 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMY Bristol Myers Squibb	$2.52	4.44%	+1.61%	70.79%	17 Years
CSLLY CSL	$0.59	3.36%	N/A	N/A	N/A
GSK GSK	$1.88	3.69%	-7.86%	48.83%	N/A
VRTX Vertex Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest CSLLY, BMY, VRTX, and GSK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/29/2026	GSK GSK	quarterly	$0.44	3.62%	5/15/2026	5/15/2026	7/9/2026
3/2/2026	BMY Bristol Myers Squibb	quarterly	$0.63	4.23%	4/2/2026	4/2/2026	5/1/2026
1/1/2100	GSK GSK	quarterly	$0.4206	4.3%	8/15/2025	8/15/2025	10/9/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMY Bristol Myers Squibb	2.10	1.42	1.28
CSLLY CSL	0.51	2.57	1.15
GSK GSK	0.80	0.79	0.52
VRTX Vertex Pharmaceuticals	N/A	3.02	2.57

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMY Bristol Myers Squibb	76.41%
CSLLY CSL	0.03%
GSK GSK	15.74%
VRTX Vertex Pharmaceuticals	90.96%

Insider Ownership

Company	Insider Ownership
BMY Bristol Myers Squibb	0.05%
CSLLY CSL	N/A
GSK GSK	10.00%
VRTX Vertex Pharmaceuticals	0.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMY Bristol Myers Squibb	32,500	2.04 billion	2.04 billion	Optionable
CSLLY CSL	29,904	1.94 billion	N/A	Not Optionable
GSK GSK	66,841	2.03 billion	1.83 billion	Optionable
VRTX Vertex Pharmaceuticals	6,400	253.80 million	253.30 million	Optionable

CSLLY, BMY, VRTX, and GSK Headlines

Recent News About These Companies

Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Atria Investments Inc

3 hours ago | marketbeat.com

Vertex Pharmaceuticals (NASDAQ:VRTX) CMO Carmen Bozic Sells 6,988 Shares

May 14 at 5:32 PM | marketbeat.com

Pacer Advisors Inc. Buys 9,641 Shares of Vertex Pharmaceuticals Incorporated $VRTX

May 14 at 5:46 AM | marketbeat.com

Bank Julius Baer & Co. Ltd Zurich Sells 10,154 Shares of Vertex Pharmaceuticals Incorporated $VRTX

May 14 at 4:22 AM | marketbeat.com

Baader Bank Aktiengesellschaft Purchases New Position in Vertex Pharmaceuticals Incorporated $VRTX

May 14 at 3:20 AM | marketbeat.com

5 Must-Read Analyst Questions From Vertex Pharmaceuticals’s Q1 Earnings Call

May 13 at 11:00 PM | finance.yahoo.com

Vertex Shareholders Endorse Board, Governance and Equity Plan

May 13 at 5:11 PM | tipranks.com

Crossmark Global Holdings Inc. Decreases Stock Position in Vertex Pharmaceuticals Incorporated $VRTX

May 13 at 3:54 AM | marketbeat.com

Halozyme Q1 Beat Driven by Royalty Outperformance, Strong Demand, Morgan Stanley

May 12 at 3:11 PM | finance.yahoo.com

Vertex’s Germany CASGEVY Deal Highlights Growing Non CF Growth Story

May 12 at 10:10 AM | finance.yahoo.com

Provident Investment Management Inc. Has $67.67 Million Holdings in Vertex Pharmaceuticals Incorporated $VRTX

May 12 at 6:54 AM | marketbeat.com

SVB Wealth LLC Sells 4,354 Shares of Vertex Pharmaceuticals Incorporated $VRTX

May 12 at 6:18 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated $VRTX Position Boosted by NewEdge Wealth LLC

May 12 at 5:30 AM | marketbeat.com

Vertex to Participate in Upcoming May Investor Conferences

May 11, 2026 | finance.yahoo.com

Vertex to Participate in Upcoming May Investor Conferences

May 11, 2026 | businesswire.com

5 Must-Read Analyst Questions From Vertex Pharmaceuticals’s Q1 Earnings Call

May 11, 2026 | msn.com

Swiss Life Asset Management Ltd Increases Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX

May 11, 2026 | marketbeat.com

Securian Asset Management Inc. Decreases Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX

May 11, 2026 | marketbeat.com

Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by ABN AMRO Bank N.V.

May 11, 2026 | marketbeat.com

FY2027 Earnings Forecast for VRTX Issued By Erste Group Bank

May 11, 2026 | americanbankingnews.com

FY2027 Earnings Estimate for VRTX Issued By Erste Group Bank

May 11, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CSLLY, BMY, VRTX, and GSK Company Descriptions

Bristol Myers Squibb NYSE:BMY

$56.76 +0.37 (+0.66%)

Closing price 05/14/2026 03:59 PM Eastern

Extended Trading

$56.83 +0.07 (+0.12%)

As of 07:11 AM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

CSL OTCMKTS:CSLLY

$17.55 -0.24 (-1.35%)

As of 05/14/2026 03:59 PM Eastern

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

GSK NYSE:GSK

$50.91 -0.08 (-0.16%)

Closing price 05/14/2026 03:59 PM Eastern

Extended Trading

$50.10 -0.81 (-1.60%)

As of 07:21 AM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Vertex Pharmaceuticals NASDAQ:VRTX

$450.41 -2.65 (-0.58%)

Closing price 05/14/2026 04:00 PM Eastern

Extended Trading

$450.36 -0.05 (-0.01%)

As of 07:00 AM Eastern

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CSLLY, BMY, VRTX, and GSK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CSLLY, BMY, VRTX, and GSK Earnings

Compare Dividends

Latest CSLLY, BMY, VRTX, and GSK Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CSLLY, BMY, VRTX, and GSK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CSLLY, BMY, VRTX, and GSK Company Descriptions

Bristol Myers Squibb NYSE:BMY

CSL OTCMKTS:CSLLY

GSK NYSE:GSK

Vertex Pharmaceuticals NASDAQ:VRTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools